Fibrinogen may help SARS-CoV-2 evade immunity while damaging blood vessels

Blood clots form when fibrinogen, a protein floating in plasma, polymerizes into fibrin strands that seal a wound. It is one of the body's most abundant defense mechanisms. But researchers at the University of Texas at Arlington and D Y Patil International University in Pune now suspect fibrinogen may be working against us during SARS-CoV-2 infection—not as a clotting agent, but as a molecular accomplice that simultaneously hides the virus from immune detection and ferries it directly to the cells lining our blood vessels.

The hypothesis, published as a viewpoint in ACS Pharmacology & Translational Science, emerges from a simple observation about electrical charge. The spike protein that SARS-CoV-2 uses to invade cells is studded with positively charged amino acids—lysine and arginine—clustered in two key regions: the N-terminal domain and the receptor-binding domain. Fibrinogen, by contrast, carries a negative charge at body pH. This electrostatic attraction, the researchers argue, is far more than incidental chemistry. When fibrinogen binds to the spike's N-terminal domain, it acts as a molecular shield, masking the very sites that neutralizing antibodies need to recognize and attack. The virus becomes invisible to immunity.

But that is only half the story. The other end of the fibrinogen molecule—its gamma chain—is built to anchor itself to receptors on the endothelial cells that line blood vessels. These receptors include integrins and other adhesion molecules. The result is a biological tether: virus on one end, blood vessel wall on the other. The fibrinogen molecule becomes a bridge, delivering SARS-CoV-2 directly to the tissue most vulnerable to inflammatory damage.

To test whether this model was structurally plausible, the team ran molecular docking simulations—computational predictions of how molecules fit together in three-dimensional space. The results were striking. When fibrinogen was present, integrin binding to the spike protein strengthened significantly, with a binding energy of −127 ± 6 kilocalories per mole. Without fibrinogen, that same binding measured only −109.4 ± 4.9 kilocalories per mole. Meanwhile, the classical entry route through ACE2 receptors weakened in the presence of fibrinogen. The simulations suggested that fibrinogen does not merely coat the virus like a shield; it appears to reshape the spike protein itself, nudging SARS-CoV-2 away from its traditional entry pathway and toward a route that leads directly to vascular inflammation and injury.

This distinction matters clinically. Long COVID patients have been found to harbor amyloid-like fibrin microclots—tiny tangles of clotted blood protein—in their tissues. These clots are associated with tissue oxygen deprivation and cognitive symptoms. If the spike-fibrinogen complex travels within these fibrin-rich clots, the clot network could deliver viral particles directly to the lung microvasculature and hold them pressed against the endothelial surface, perpetuating inflammation and vascular damage long after the acute infection has cleared.

The researchers note that fibrinogen's alpha and beta chains, which are primarily responsible for forming fibrin clots, interact minimally with endothelial receptors. The gamma chain, by contrast, appears purpose-built for the anchoring role the model proposes. This specificity may explain why the spike protein seems to prefer binding to the gamma chain over the others.

The idea did not emerge in isolation. Recent work has shown that cationic nanoparticles in the bloodstream attract fibrinogen and other plasma proteins, creating a coating that enables targeted delivery without triggering unwanted clotting. The researchers suggest that viruses and engineered nanocarriers may be exploiting the same underlying physics—using coagulation proteins as biological adaptors that determine where anything entering the bloodstream ultimately settles. This principle could cut both ways: understanding how fibrinogen guides SARS-CoV-2 to endothelial cells might help design safer RNA delivery vehicles, while blocking the spike-fibrinogen interface could open new therapeutic approaches for both acute COVID-19 and the vascular complications of long COVID.

The authors are careful to emphasize that their hypothesis remains computational and preliminary. Experimental validation is needed to confirm whether fibrinogen genuinely increases integrin binding to the spike protein and whether this mechanism actually mediates viral entry into endothelial cells in living tissue. But if the model holds, it would offer a single mechanistic explanation for two features of COVID-19 that have long been treated as separate puzzles: the virus's uncanny ability to evade immunity and the vascular damage, microclotting, and inflammation that characterize severe disease and its long-term aftermath.